Evidence map›Paper›PMID 37577750›Full record

ArticleFrontiers in molecular biosciences2023

Multi-omics analysis of LAMB3 as a potential immunological and biomarker in pan-cancer.

Yanghao Wang, Guoyu Li, ZhiYuan Wang, Weizhou Wang, Xiaofang Wang, Xuan Luo, Juan Zhao, Fangfang Li, Li Bian

Open access · goldAbstract read
In one paragraph

Article in Frontiers in molecular biosciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Yanghao WangDepartment of Pathology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Guoyu LiDepartment of Pathology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
ZhiYuan WangDepartment of Pathology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Weizhou WangDepartment of Orthopedics, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Xiaofang WangDepartment of Pathology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Xuan LuoDepartment of Pathology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Juan ZhaoDepartment of Pathology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Fangfang LiDepartment of Pathology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Li BianDepartment of Pathology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China.
Kunming Medical University · CNFirst Affiliated Hospital of Kunming Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Laminin Subunit Beta 3 (LAMB3) is a transcription factor and participates in the coding of laminin. It plays an important role in cell proliferation, adhesion, and transfer by regulating various target genes and signaling pathways. However, the role of LAMB3 in human pan-cancer immunology and prognosis is still poorly understood. The TCGA, GTEx, CCLE, and HPA databases were utilized for the analysis of LAMB mRNA and protein expression. The expression of LAMB3 in various immune and molecular subtypes of human cancer was examined using the TISIDB database. The prognostic significance of LAMB3 in various cancers and clinical subtypes was investigated using Kaplan-Meier and Cox regression analysis. The relationship between LAMB3 expression, various immune cell infiltration, immune checkpoints, tumor mutational load, microsatellite instability, and DNA methylation was examined using the TCGA database. Clinical samples of four lung cancer cell lines and eight lung cancer cases were collected to confirm the expression of mRNA in lung cancer. In 17 cancers, the mRNA for LAMB3 is expressed differently and has good diagnostic and prognostic value in 22 cancers. Cox regression and Nomogram analysis show that LAMB3 is an independent risk factor for 15 cancers. LAMB3 is implicated in a variety of tumorigenesis and immune-related signaling pathways, according to GO, KEGG, and GSEA results. LAMB3 expression was associated with TMB in 33 cancer types and MSI in 32 cancer types, while in lung cancer LAMB3 expression was strongly associated with immune cell infiltration and negatively correlated with all seven methylated CpG islands. Cellular experiments demonstrated that LAMB3 promotes malignant behavior of tumor cells. Preliminary mechanistic exploration revealed its close association with PD-L1, CTLA4, cell stemness gene CD133 and β-catenin-related signaling pathways. Based on these findings, it appears that LAMB3 could be a potential therapeutic target for immunotherapy and tumor prognosis. Our findings reveal an important role for LAMB3 in different cancer types.

Indexed as

biomarkerLAMB3multi-omicspan-cancertumor immunity

Identifiers

PMID37577750
PMCPMC10415034
OpenAlexW4385325189

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.